You are here

  • Home
  • Archive
  • Volume 32, Issue Suppl 2
  • 2022-RA-1198-ESGO Post hoc analysis of objective response rate by mismatch repair protein dimer loss/mutation status in patients with mismatch repair deficient endometrial cancer treated with dostarlimab

Citation Tools

Article menu

Download PDFPDF

Translational research/biomarkers
2022-RA-1198-ESGO Post hoc analysis of objective response rate by mismatch repair protein dimer loss/mutation status in patients with mismatch repair deficient endometrial cancer treated with dostarlimab
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Tinker AV, Sabatier R, Gravina A, et al
2022-RA-1198-ESGO Post hoc analysis of objective response rate by mismatch repair protein dimer loss/mutation status in patients with mismatch repair deficient endometrial cancer treated with dostarlimab
International Journal of Gynecologic Cancer 2022;32:A414.